Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

QRX-101 phase II trial in psoriasis cleared to begin

Jan. 24, 2003

Efficacy of TAK-427 in experimental model of atopic dermatitis

Jan. 23, 2003

Positive phase III results for Enbrel in psoriasis

Jan. 21, 2003

Tacrolimus reported safe and effective in chronic actinic dermatitis

Jan. 20, 2003

Shire licenses Solaraze rights in Australia and certain Pacific Rim territories

Jan. 17, 2003

Access licenses amlexanox to Zambon

Jan. 16, 2003

Velac enters phase III development program for acne

Jan. 9, 2003

Proof of concept established in patients for Arachnova's product for dermatitis

Jan. 9, 2003

Finacea approved for topical treatment of rosacea

Jan. 9, 2003

BMS claims new antagonists of LFA-1 and Mac-1/ICAM interaction

Jan. 8, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...